Dr. Reddy's Laboratories
DRREDDY
Dr. Reddy's Laboratories Market Sentiment
| Timeline | Returns | Volume |
|---|---|---|
| Daily | 1.97% | 4,85,298 |
| Weekly | 3.97% | 19,08,743 |
| Monthly | 13.61% | 85,24,533 |
Dr. Reddy's Laboratories Performance
| Timeline | Daily | Weekly | Monthly |
|---|---|---|---|
| DRREDDY | 1.97% | 3.97% | 13.61% |
| Index | - | - | - |
| Peer Avg. | 2.28% | 1.01% | 2.35% |
Dr. Reddy's Laboratories Fundamentals
| Timeline | PE | PB | EV/EBIDTA | ROE | ROCE | Div. Yield |
|---|---|---|---|---|---|---|
| DRREDDY | 38.48 | 3.85 | 12.92 | 10.40 | 12.97 | 0.69 |
| Index | 35.44 | 5.98 | 16.81 | 16.99 | 18.41 | 1.19 |
| Peer Avg. | 35.31 | 3.95 | 12.55 | 16.53 | 7.42 | 2.36 |
Dr. Reddy's Laboratories Key Metrics
| Metrics | Sales Growth | Profit Growth | ROE | ROCE |
|---|---|---|---|---|
| FY '21-22 | 10.51% | -7.40% | 10.40% | 12.97% |
| FY '20-21 | 10.69% | -14.47% | 12.61% | 16.52% |
| FY '19-20 | 12.46% | 66.67% | 17.30% | 14.69% |
Dr. Reddy's Laboratories Shareholding Pattern
Dr. Reddy's Laboratories Profit & Loss
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| FY '21-22 | 17,975.20 | 14,794.45 | 3,664.10 | 1,867.70 |
| FY '20-21 | 16,198.30 | 12,694.95 | 4,049.60 | 2,045 |
| FY '19-20 | 14,683.70 | 12,013.70 | 3,351.90 | 2,453.80 |
Dr. Reddy's Laboratories Share Price
Dr. Reddy's Laboratories Limited is an Indian global pharmaceutical company. The company offers a wide range of products and services, including active ingredients (APIs), generics, generic brands, biosimilars and OTC products. Its main therapeutic focus areas are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. The company's segments include Pharmaceutical Services and Active Ingredients, Global Generics and others. The Pharmaceutical Services and Active Ingredients Segment consists primarily of the Company's API and intermediate manufacturing and distribution business. The Global Generics segment consists of the Company's business, which manufactures and markets prescription and over-the-counter drugs that are ready for patient consumption, marketed under a brand name (branded formulations) or generic usable dosages that are therapeutically equivalent to brand name products (generic).